At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed May 1, 2026 at 12:43 ET
Arvinas (ARVN) announced FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC therapy, for ER+/HER2- ESR1-mutated advanced breast cancer after prior endocrine therapy. The approval came ahead of the PDUFA date and is based on the VERITAC-2 trial showing a 43% reduction in risk of disease progression or death vs fulvestrant (HR 0.57). This transformative milestone validates the PROTAC platform and provides a new treatment option for a significant unmet need, though commercial execution and competition remain risks.
- First FDA-approved PROTAC therapy (VEPPANU/vepdegestrant), approved ahead of June 5, 2026 PDUFA date
- Indication: ER+/HER2- ESR1-mutated advanced or metastatic breast cancer after ≥1 line of endocrine therapy
- VERITAC-2 Phase 3 trial (N=270 ESR1m) showed median PFS 5 months vs 2.1 months for fulvestrant (HR 0.57, p=0.0001)
- Discovered by Arvinas, jointly developed with Pfizer; companies plan to select a third-party partner for commercialization
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access